Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357119 | 0.82 | BRD4 (0.37) | LMNAMAPTBRD4L3MBTL1KDM4E | |
| SCHEMBL11714174 | 0.82 | TSHR (0.37) | LMNAHSD17B10MAPTBRD4TSHR | |
| SCHEMBL22678925 | 0.82 | MAPK1 (0.39) | LMNAHSD17B10MAPTBRD4TSHR | |
| SCHEMBL23900422 | 0.79 | BRD4 (0.54) | LMNAHSD17B10MAPTBRD4TSHR | |
| SCHEMBL1310640 | 0.77 | BRD4 (0.38) | BRD4L3MBTL1KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL17215917 | 0.76 | LMNA (0.35) | LMNAHSD17B10MAPTL3MBTL1KDM4E | |
| SCHEMBL16401887 | 0.74 | GSK3A (0.47) | MAPTBRD4TSHRL3MBTL1KDM4E | |
| SCHEMBL4620955 | 0.74 | MCL1 (0.41) | LMNAHSD17B10MAPTTSHRTP53 | |
| SCHEMBL16021999 | 0.73 | PDE4A (0.42) | L3MBTL1ADORA2B | |
| SCHEMBL31091404 | 0.73 | NOTUM (0.51) | LMNAMAPTTP53KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103958497-B | uracil derivatives as AXL and c-MET kinase inhibitors | 亚尼塔公司 | 2017-09-01 | — | — | CN | claimed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-4045036-B1 | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12533354-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12497383-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250361223-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2025-11-27 | — | — | US | disclosed |
| US-12435062-B2 | Amide compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| US-20240374583-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-11-14 | — | — | US | disclosed |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| CN-103958497-A | Uracil derivatives as AXL and c-MET kinase inhibitors | CEPHALON INC | 2014-07-30 | — | — | CN | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-4052507-A | HYPOGLYCEMIC | PFIZER INC. (US) | 1977-10-04 | — | — | US | disclosed |
| US-4052507-A | HYPOGLYCEMIC | PFIZER INC. (US) | 1977-10-04 | — | — | US | disclosed |
| US-3998828-A | ORAL HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1976-12-21 | — | — | US | disclosed |
| US-3998828-A | ORAL HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1976-12-21 | — | — | US | disclosed |
| US-3953428-A | ANTIBACTERIAL | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
| US-3936455-A | ORAL HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1976-02-03 | — | — | US | disclosed |
| US-3936455-A | ORAL HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497383-B2 | Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | LMNA 1671/4885HSD17B10 2558/4885MAPT 4119/4885 |
| US-12533354-B2 | Triaryl compounds for treatment of PD-L1 diseases | CD274, PDCD1LG2, PDCD1 | LMNA 1174/4885HSD17B10 672/4885MAPT 4110/4885 |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | LMNA 1610/4885HSD17B10 1376/4885MAPT 4312/4885 |
| US-12435062-B2 | Amide compounds and uses thereof | ASNS, ASS1, NAT1 | LMNA 3803/4885HSD17B10 582/4885MAPT 1147/4885 |
| US-20240374583-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | OPRD1, OPRM1, OPRK1 | LMNA 936/4885HSD17B10 2331/4885MAPT 229/4885 |
| US-20250361223-A1 | AMIDE COMPOUNDS AND USES THEREOF | ASNS, NAT1, AADAC | LMNA 3547/4885HSD17B10 602/4885MAPT 862/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | LMNA 3405/4885HSD17B10 4782/4885MAPT 2880/4885 |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | LMNA 2102/4885HSD17B10 712/4885MAPT 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.